Jason Pogue, PharmD, BCPS-ID, explains the limitations of the current drugs for the treatment of Pseudomonas aeruginosa infections.
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains the limitations of the current drugs for the treatment of Pseudomonas infections.
Interview Transcript (slightly modified for readability)
“The limitation of the current drugs for the treatment of Pseudomonas [aeruginosa] is simple. Even our best anti-Pseudomonal agents that we currently had, at least until a couple of years ago, come with a 15% to 20% resistance rate. So, we run into a lot of situations where we can’t use our first-line agents to treat these infections, and we’re forced to use toxic suboptimal therapies instead.”
DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.